Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 9, 2025Open Access

Objective Response by mRECIST is an Independent Prognostic Factor for Overall Survival in Intermediate Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

View Full Paper
Ask AI
Bookmark
Share

Authors

XJXiaowei JiaWWWenjun Wang

Discussion

Loading...

Member takes

Overview

Retrospective analysis of 812 patients with HCC undergoing TACE shows mRECIST as a key prognostic factor for survival.

Key Points

  • Responders to TACE exhibit longer overall survival of 44.0 months, compared to 10.9 months in non-responders, indicating response significance.
  • The objective response rate using mRECIST was 63.2%, demonstrating substantial effectiveness of TACE in intermediate HCC patients.
  • Cox regression analysis identified objective response, tumor size, tumor number, and alpha-fetoprotein as key prognostic factors for overall survival.
  • Findings underscore the importance of achieving early objective response in HCC treatment to enhance survival outcomes.

Cite This Study

Jia et al. (2025) studied this question.

synapsesocial.com/papers/68e70db790569dd607ee67dfhttps://doi.org/10.1101/2025.10.05.25337382
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Radiological Response and Characteristics of Patients Diagnosed With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: An Observational Study.2025 · 1 citations
  2. 2Use of Initial Modified RECIST Tumor Response Evaluation Criteria for Predicting Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization with Drug-Eluting Beads2015 · 2 citations
  3. 3Predictors of outcome of transarterial locoregional therapies in unresectable hepatocellular carcinoma: a multicenter analysis2026
  4. 4Assessment of Preprocedural Factors Associated with 5-Year Complete Response After Transarterial Radioembolization in Patients with Hepatocellular Carcinoma2025
  5. 5Depth of radiographic response as an independent prognostic factor for patients with initially unresectable hepatocellular carcinoma receiving hepatectomy following targeted therapy plus immunotherapy2024 · 2 citations